ArticleJCO global oncology2026
Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.
Article in JCO global oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the treatment of B-cell precursor ALL (B-ALL), but its global availability is limited. This study assessed current access and barriers to CAR-T CD19 therapy for children across Europe. MATERIALS AND
methodsA country questionnaire developed by the European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party, St Jude Children's Research Hospital, and IBFM assessed current access to advanced therapies for B-ALL in Europe using Qualtrics software.
resultsData from 36 WHO-defined European countries (27 high-income, nine upper-middle-income) observed a median of five pediatric hematology-oncology (PHO) centers per country (0.56 PHO centers/1 million inhabitants, range, 0.05-1.83). Hematopoietic stem-cell transplantation (HSCT) facilities were available in 89% of countries (32/36). CAR-T CD19 therapy was available in 72% of countries; however, 25/36 (69%) countries lacked clinical trials or international collaborations for pediatric CAR-T CD19 therapy. Most countries accepted foreign patients, but referrals remained limited, with 1-2 foreign patients treated annually per country. Eighteen countries expressed interest in a referral network, but only six had established mechanisms for domestic or international referrals.
conclusionSubstantial disparities exist in access to advanced therapies for pediatric B-ALL across Europe. Although CAR-T CD19 therapy is available in most countries, gaps in clinical trials, collaborations, and referral systems limit equitable access. Efforts to improve infrastructure and establish referral networks are essential to enhance care for patients with pediatric B-ALL.
Indexed as
Identifiers
42241651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.